ANDA 63065, held by Watson Laboratories. Minocycline Hydrochloride.
As of Nov 22, 2026, ANDA 63065 (Minocycline Hydrochloride), held by Watson Laboratories, was first approved by FDA on Dec 30, 1991, with 24 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 30, 1991 | Original application | Approved |
| Minocycline HydrochlorideEQ 100MG BASE ยท capsule;oral | Minocycline Hydrochloride | Rx |
| Minocycline HydrochlorideEQ 75MG BASE ยท capsule;oral | Minocycline Hydrochloride | Rx |
| May 12, 2026 | Supplement 64Labeling ยท Standard review | Approved | None posted |
| May 12, 2026 | Supplement 63Labeling ยท Standard review | Approved | None posted |
| May 5, 2020 | Supplement 59Labeling ยท Standard review | Approved | None posted |
| May 5, 2020 | Supplement 58Labeling ยท Standard review | Approved | None posted |
| May 5, 2020 | Supplement 56Labeling ยท Standard review | Approved | None posted |
| Nov 20, 2008 | Supplement 44Labeling | Approved | None posted |
| Apr 25, 2008 | Supplement 40Labeling | Approved | None posted |
| Oct 22, 2001 | Supplement 20Labeling | Approved | None posted |
| Oct 22, 2001 | Supplement 19Manufacturing | Approved | None posted |
| Apr 25, 2001 | Supplement 18Manufacturing | Approved | None posted |
| Jun 10, 1999 | Supplement 15Labeling | Approved | |
| Jun 10, 1999 | Supplement 14Manufacturing | Approved | |
| Jun 2, 1999 | Supplement 17Manufacturing | Approved | None posted |
| Dec 9, 1998 | Supplement 13Manufacturing | Approved | None posted |
| May 12, 1998 | Supplement 9Manufacturing | Approved | None posted |
| May 12, 1998 | Supplement 8Manufacturing | Approved | None posted |
| Apr 7, 1998 | Supplement 12Manufacturing | Approved | None posted |
| Apr 7, 1998 | Supplement 11Manufacturing | Approved | None posted |
| Apr 7, 1998 | Supplement 10Manufacturing | Approved | None posted |
| Nov 5, 1997 | Supplement 7Manufacturing | Approved | None posted |
| May 8, 1996 | Supplement 5Labeling | Approved | None posted |
| Mar 4, 1996 | Supplement 65Labeling | Approved | None posted |
| Mar 4, 1996 | Supplement 3Labeling | Approved | None posted |
| Jul 22, 1992 | Supplement 1Manufacturing | Approved | None posted |
| Dec 30, 1991 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters